The impact of chemotherapy-induced nausea and vomiting on health-related quality of life

Supportive Care in Cancer

Volumn 15, Issue 2, 2007, Pages 179-185

  Ballatori, Enzo ^a   Roila, Fausto ^b   Ruggeri, Benedetta ^c   Betti, Maura ^b   Sarti, Samanta ^d   Soru, Giancarla ^e   Cruciani, Giorgio ^f   Di Maio, Massimo ^g   Andrea, Biffi ^h   Deuson, Robert R ⁱ  

^a UNIVERSITY OF L'AQUILA   (Italy)

^b Policlinic Hospital   (Italy)

^c ZT 13 ^*  (Italy)

^d UNIVERSITY OF PISA   (Italy)

^e SS Annunziata Hospital   (Italy)

^f Ospedale Civile   (Italy)

^g National Cancer Institute   (Italy)

^h SAN CARLO BORROMEO HOSPITAL   (Italy)

ⁱ MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Activities of daily living; Chemotherapy induced nausea and vomiting; Functional Living Index for Emesis (FLIE) questionnaire; Quality of life

Indexed keywords

CISPLATIN; CORTICOSTEROID; FLUOROURACIL; GEMCITABINE; METOCLOPRAMIDE; SEROTONIN 3 ANTAGONIST;

ADULT; ARTICLE; CANCER PATIENT; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DISEASE DURATION; DISEASE SEVERITY; DRUG INDUCED DISEASE; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; QUESTIONNAIRE; TREATMENT OUTCOME;

AGED; ANTIEMETICS; ANTINEOPLASTIC AGENTS; CISPLATIN; FEMALE; HUMANS; ITALY; MALE; MIDDLE AGED; NAUSEA; OBSERVATION; PROSPECTIVE STUDIES; QUALITY OF LIFE; VOMITING;

EID: 33847404360     PISSN: 09414355     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00520-006-0109-7     Document Type: Article

References (24)

1. Aapro MS, Molassiotis A, Olver I (2005) Anticipatory nausea and vomiting. Support Care Cancer 13:117-121
2. Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC) (1998) Prevention of chemotherapy- and radiotherapy-induced emesis: results of Perugia Consensus Conference. Ann Oncol 9:811-819
3. Ballatori E (2001) Unsolved problems in evaluating the quality of life of cancer patients. Ann Oncol 12(Suppl 3):S11-S13
4. Ballatori E, Roila F (2003) Impact of nausea and vomiting on quality of life in cancer patients during chemotherapy. Health Qual Life Outcomes 1:46-58
5. de Boer-Dennert M, de Wit R, Schmitz PI et al (1997) Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists. Br J Cancer 76:1055-1061
6. Fabi A, Barduagni M, Lauro S et al (2003) Is delayed chemotherapy-induced emesis well managed in oncological clinical practice? An observational study. Support Care Cancer 11:156-161
7. Glaus A, Knipping C, Morant R et al (2004) Chemotherapy-induced nausea and vomiting in routine practice: a European perspective. Support Care Cancer 12:708-715
8. Gralla RJ, Osoba D, Kris MG et al (1999) Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. American Society of Clinical Oncology. J Clin Oncol 17:2971-2994
9. Griffin AM, Butow PN, Coates AS et al (1996) On the receiving end. V: patient perceptions of the side effects of cancer chemotherapy in 1993. Ann Oncol 7:189-195
10. Grunberg SM, Deuson RR, Mavros P et al (2004) Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer 100: 2261-2268
11. Grunberg SM, Osoba D, Hesketh PJ et al (2005) Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity - an update. Support Care Cancer 13:80-84
12. Italian Group for Evaluation of Outcomes in Oncology (IGEO) (1999) Patient compliance with quality of life questionnaires. Tumori 85:92-95
13. Kris MG, Hesketh PJ, Herrstedt J et al (2005) Consensus proposals for the prevention of acute and delayed vomiting and nausea following high-emetic-risk chemotherapy. Support Care Cancer 13:85-96
14. Lindley CM, Hirsch JD, O'Neill CV et al (1992) Quality of life consequences of chemotherapy-induced emesis. Qual Life Res 1:331-340
15. Martin AR, Pearson JD, Cai B et al (2003) Assessing the impact of chemotherapy-induced nausea and vomiting on patients' daily lives: a modified version of the Functional Living Index - Emesis (FLIE) with 5-day recall. Support Care Cancer 11:522-527
16. Osoba D, Zee B, Warr D et al (1997) Effect of postchemotherapy nausea and vomiting on health-related quality of life. The Quality of Life and Symptom Control Committees of the National Cancer Institute of Canada Clinical Trials Group. Support Care Cancer 5:307-313
17. Roila F, Donati D, Tamberi S et al (2002) Delayed emesis: incidence, pattern, prognostic factors and optimal treatment. Support Care Cancer 10:88-95
18. The Antiemetic Subcommittee of the Multinational Association of Supportive Care in Cancer (MASCC) (2006) Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol 17:20-28
19. The Italian Group For Antiemetic Research (1992) Ondansetron + dexamethasone vs metoclopramide + dexamethasone + diphenhydramine in prevention of cisplatin-induced emesis. Lancet 340:96-99
20. The Italian Group for Antiemetic Research (1995) Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer. N Engl J Med 332:1-5
21. The Italian Group of Antiemetic Research (1995) Ondansetron versus granisetron, both combined with dexamethasone, in the prevention of cisplatin-induced emesis. Ann Oncol 6:805-810
22. The Italian Group for Antiemetic Research (1997) Ondansetron versus metoclopramide, both combined with dexamethasone, in the prevention of cisplatin-induced delayed emesis. J Clin Oncol 15:124-130
23. The Italian Group for Antiemetic Research (2000) Dexamethasone alone or in combination with ondansetron for the prevention of delayed nausea and vomiting induced by chemotherapy. N Engl J Med 342:1554-1559
24. Uyl-de Groot CA, Wait S, Buijt I (2000) Economics and health-related quality of life in antiemetic therapy: recommendations for trial design. Eur J Cancer 36:1522-1535